Akriveia Therapeutics is discovering and developing the next generation of cancer immunotherapies. Akriveia’s new agents offer the promise of a safer and more efficacious approach to harness a patient’s own immune system to attack cancer.
About our name: “Akriveia” is a Greek word meaning “Precision” or “Accuracy” and reflects our mission to develop best-in-class immunotherapeutics through the precise targeting of our therapeutics to tumors.
CEO: Simon Tomlinson
CSO: C. Glenn Begley
Co-Founder and Member of Scientific Advisory Board: Uli Rodeck
Co-Founder and Member of Scientific Advisory Board: John C. Williams
Vice President, Discovery and Preclinical Development: Margaret Karow
Please click here for Akriveia's job opportunities.